Lipocine (LPCN) risk factors
Item 1A of every Lipocine Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors55 risks1 new4 dropped11 reworded
Accumulated deficit increased to $209.4 million as of December 31, 2025. Third-party supply and patent risks added for LPCN 1154. Tariffs added as a commercialization risk for TLANDO.
Filed Mar 10, 2026 - FY2024 10-K risk factors58 risks
Lipocine faces heavy regulatory, clinical, and commercial risks centered on its developmental neuroactive steroid and testosterone replacement portfolios. The company is heavily reliant on third-party single suppliers for active pharmaceutical ingredients and external partners for commercialization. Operations are entirely dependent on clinical trial success, FDA approvals, and adequate healthcare reimbursement.
Filed Mar 13, 2025